Bioquell ProteQ offers major cost benefits, a modular, upgradeable design and new features including wireless connectivity, built-in aeration & graphical user interface. Bioquell a leading global expert in reducing the risk of bio-contamination in the pharmaceutical, life science and healthcare markets - has launched the cost effective and high performance Bioquell ProteQ mobile room bio-decontamination system. Utilising the company’s 35% hydrogen peroxide vapour and boasting a modular, upgradeable design for a...

Increasing demand from the global gene and cell therapy industry as well as sterility testing applications for medical devices, pharmaceuticals and tissue samples. Bioquell UK Ltd one of the leading global experts in reducing the risk of bio-contamination in the healthcare, life science and pharmaceutical markets. is celebrating the sale of its 200th Bioquell Qube from its state-of-the-art facility in Andover in the UK. This milestone high performance isolator has been supplied to a major international pharmaceutical company....

The only modular isolator to offer built in Bioquell Hydrogen Peroxide Vapor technology for rapid bio-decontamination, reduced risk and major cost benefits. One of the leading global experts in reducing the risk of bio-contamination in the Life Science market – highlighted the suitability of its state-of-the-art Bioquell Qube aseptic workstation for the rapidly emerging CAR-T and gene and cell therapy sector. The isolator, which can be customised to suit the individual needs of cell therapy...

The latest innovative bio-decontamination technology to revolutionise pass-through chamber and cleanroom aseptic practices, has just been launched by the world’s leading decontamination experts.

The Bioquell FS-1 is a fixed system, designed to be rapidly installed and validated, overcoming many of the issues and challenges observed in pharmaceutical production and life science research. Based on Bioquell’s well proven gold-standard technology, the FS-1 delivers swift bio-decontamination cycles to a 6-log reduction whilst leaving no residues.....

With the impending legal requirements about to affect the life science and healthcare sectors, a leading decontamination expert has developed a quick overview to help explain the impact from the next phase of the Biocidal Products Regulation (BPR).

This new white paper written by John Chewins, director of the scientific & regulatory affairs at Bioquell, highlights that the introduction of the second phase of the BPR will mean some biocidal products currently legally placed on the market may no longer be legal....

Infection rates in hospitals significantly reduced by using hydrogen peroxide vapour technology, reports latest scientific study.

A marked decrease was observed for C difficile, MRSA, VRE and EBSL following the room/environmental disinfection treatment and ongoing improvements in hand hygiene. Published in the American Journal of Infection Control, the paper by Kim Horn MPH and Jonathan A. Otter PhD shows the result of a before-after study conducted from October 2010 to September 2013. The impact of the implementation of HPV room disinfection...

Smaller, faster and with the gold standard in pathogen killing efficacy, the next generation of microbial eradication technology has just been launched by the world leader in bio-decontamination.

The Bioquell BQ-50 is the result of an innovative R&D endeavour conducted by Bioquell following in-depth market research. Using the latest hydrogen peroxide vapour (HPV) technology to eradicate pathogens, the company has been developing this new system to provide the healthcare sector with an even more efficient and flexible bio-decontamination process. The BQ-50 works by depositing an even layer of ‘micro-condensation’ of HPV over all surfaces to eradicate...

Hydrogen peroxide-based automated room decontamination (ARD) systems for hospitals have received lots of attention in recent years.

Their efficacy at eliminating unwanted pathogens from surfaces makes them ideal for infection control in hospitals and bioburden management in pharmaceutical production. Several systems are available on the market, typically hydrogen peroxide vapour from 35% w/w hydrogen peroxide (HPV) and aerosolised hydrogen peroxide from 5-6% w/w hydrogen peroxide (AHP). Although in principle, both systems use hydrogen peroxide...

After a Nigerian UN peacekeeper contracted Ebola and was transported to the Netherlands for treatment, advanced decontamination technology was deployed to minimise the risk of cross-infection.

The University Medical Centre (UMC) in Utrecht called the local representative of a UK decontamination specialist to intervene on an isolation suite where the patient had been hospitalised. Using hydrogen peroxide vapour (HPV) technology, capable of eliminating 99.9999% of pathogens, Bioquell technology was used to neutralise the risks of any cross-contamination. The Netherlands as well as other European countries have agreed...

Following a recent Ebola virus disease (EVD) patient being discharged from a Glasgow hospital and transferred by military plane to a specialist north London centre, Bioquell technology was again called into action.

The Hampshire-based company was commissioned to deploy its hydrogen peroxide vapour (HPV) technology - the gold standard in bio-decontamination. The firm’s HPV process kills 99.9999% of pathogens, eliminating doubt by destroying biological threats in healthcare and life science environments. The patient, a nurse who contracted the Ebola virus while working in Sierra Leone, returned back to the UK before being...

Reducing infection transmission risk on a paediatric high dependency unit was just one of the topics under discussion at Lyon, France on the first day of the Healthcare Infection Society Conference 2014.

A study showing how the Bioquell Pod has benefited the Alder Hey Children’s NHS Foundation Trust was presented to leading healthcare professionals. The Bioquell Pod is an infection control enclosure that has been designed to limit the spread of pathogens in ward environments and can be used to convert units into single occupancy rooms. It facilitates infection control management by segregating patients while offering easy...

With Ebola cases reaching the USA, the public has become more conscious about infectious diseases and infection control.

Hospitals face the challenge of infection prevention on a daily basis. Whilst some are in the process of setting up Ebola preparedness protocols, some like the Rome Memorial Hospital, New York, are already fully equipped to handle a case should it present itself. As broadcasted in two features on WKTV News and CNY, Rome Memorial already uses Bioquell’s hydrogen peroxide vapour (HPV) technology to fight more common infections...

West Park Hospital in Cody, Wyoming, has adopted the Bioquell robotic technology used to decontaminate rooms and ambulances that have had contact with Ebola patients.

Featured by KULR News on Thursday 23d October, the hospital purchased the equipment long before the Ebola outbreak in Dallas. The system is used in hospitals around the world to kill more common pathogens such as CPE, C.difficile or norovirus Gerri Ackley Infection Preventionist at Cody’s West Park Hospital, who’s concerned about multi-drug resistant bugs and other infectious agents, says, "We're going into flu season. And, frankly that's one of...

A series of solutions for NHS hospitals designed to face the growing threat of Ebola have been developed by specialist infection control experts in the UK.

With flexible single patient infection control enclosures that can be erected without the need to close a unit, and powerful bug killing robotic technology, global bio-decontamination leader Bioquell is all set to help heathcare professionals minimise any infectious spread. Western hospitals are facing a challenge when confronted to the risk of Ebola contamination.  The UK Department of Health has issued infection prevention...

Superbugs - like persistent C. difficile and MRSA -threaten hospitals all around the UK where infection control is a high priority area.

Many hospitals have introduced C. difficile reduction targets or have had these mandated by government bodies or regulators. When it comes to eliminating doubt, hospitals need efficient, secure and time-saving solutions to protect patients from infection risks. The challenge of infection control and successful outbreak management is one that the Bioquell team have chosen to take on...

In response to the superbug red alert warning raised by England's main public health body, a UK firm has detailed a range of support measures that are effective against CPE.

Carbapenemase-producing enterobacteriaceae (or CPE) has outgrown the term ‘superbug’ due to the highly limited treatment options available. Such is the level of concern that the pathogen has been called “a national health threat” by NHS officials. To combat this threat Public Health England (PHE) has issued a toolkit to help NHS trusts combat CPE. And the UK's leading experts in tackling the superbug menace have now developed a range of solutions to support the implementation of two key areas of this toolkit: environmental decontamination and patient isolation...

Clostridium difficile and norovirus appear to be the main causes of concern for infection control professionals as we enter the winter months according to the latest survey.

Conducted at Infection Prevention 2013, the survey revealed that 48% of the respondents highlighted C difficile as the primary cause of concern and 36% highlighted norovirus. Carried out by Bioquell, a provider of no-touch infection control solutions to the healthcare industry, the survey of 170 infection control nurses and senior practitioners were asked to rank various pathogens in order of priority and also indicate any others that they were concerned about....

A bundle of infection control measures using the latest hydrogen peroxide vapour (HPV) disinfection technology has significantly reduced the incidence of nosocomial MRSA and Acinetobacter baumannii in one of Europe's leading burns units